Celiac Panel: How to Interpret Your Results

What a Celiac Panel Actually Measures

A celiac panel is a group of blood tests that detect antibodies produced when the immune system reacts to gluten, a protein found in wheat, barley, and rye. The panel typically includes three to four markers: tissue transglutaminase IgA (tTG-IgA), deamidated gliadin peptide antibodies (DGP-IgA and DGP-IgG), endomysial antibody IgA (EMA-IgA), and total serum IgA. Each marker serves a distinct diagnostic purpose.

The American College of Gastroenterology (ACG) 2013 clinical guideline, authored by Rubio-Tapia et al., recommends tTG-IgA as the single best screening test for celiac disease in patients over age 2 who are consuming a gluten-containing diet. Total IgA is run alongside it because roughly 2-3% of celiac patients have selective IgA deficiency, which renders all IgA-based markers falsely negative [1]. When IgA deficiency is present, DGP-IgG becomes the preferred alternative marker. EMA testing, while highly specific, is labor-intensive (it uses indirect immunofluorescence on primate tissue) and is typically reserved for confirmation rather than initial screening.

The panel is not a single number. It is a pattern. Interpreting it correctly means reading each marker in context with the others, your symptoms, and your current gluten intake [2].

tTG-IgA: The Anchor of the Panel

Tissue transglutaminase IgA is the workhorse of celiac serology because it combines high sensitivity (93-96%) with high specificity (97-98%), according to a systematic review published in Gastroenterology by Rostom et al. [3]. Most labs report the result in units per milliliter (U/mL), with a reference range that varies by assay. A common cutoff is <4 U/mL for negative, 4-10 U/mL for weak positive, and >10 U/mL for positive.

What matters clinically is not just whether the test is positive but how high it is. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2020 guideline established that a tTG-IgA level ≥10 times the upper limit of normal (≥10x ULN), confirmed by a positive EMA on a second blood draw, can diagnose celiac disease in children without duodenal biopsy [4]. For example, if your lab's upper limit of normal is 7 U/mL, a result of 70 U/mL or higher meets this threshold.

Strong positives correlate with more severe villous atrophy. A 2019 study by Singh et al. in Clinical Gastroenterology and Hepatology found that tTG-IgA levels ≥10x ULN predicted Marsh 3 histology (total or subtotal villous atrophy) with a positive predictive value of 95.4% [5]. The higher the number, the more confident the diagnosis.

False positives do occur. Conditions that can produce mildly elevated tTG-IgA without celiac disease include type 1 diabetes, autoimmune liver disease, chronic heart failure, and inflammatory bowel disease [6]. These are typically low-level elevations (less than 2-3x ULN), which is one reason the 10x threshold is so diagnostically useful.

Total IgA: The Hidden Make-or-Break Test

Total serum IgA is often overlooked on the panel, but it determines whether your other results can be trusted. Selective IgA deficiency occurs in about 1 in 400-800 people in the general population, but in celiac patients the rate is 10 to 15 times higher, affecting 2-3% of confirmed cases [7].

If your total IgA is below the lab's lower reference limit (typically <7 mg/dL), every IgA-based marker on the panel becomes unreliable. A "negative" tTG-IgA or EMA-IgA in this scenario is meaningless. Your clinician should reflexively order DGP-IgG and tTG-IgG, which are not affected by IgA deficiency [1].

This is a common missed diagnosis pathway. A patient with IgA deficiency, chronic diarrhea, and iron-deficiency anemia can have a completely normal-looking celiac panel. The ACG guideline explicitly states: "IgA deficiency should be identified... as false-negative IgA-based serological tests may occur" [1]. Always check whether total IgA was included on your panel report. If it was not measured, the negative results carry less weight.

Endomysial Antibody (EMA): The Confirmation Test

EMA-IgA is the most specific serological marker for celiac disease, approaching 99-100% specificity in most studies [3]. It detects antibodies against the endomysium, the connective tissue surrounding smooth muscle fibers in the gut. Unlike tTG-IgA, which is reported as a continuous number, EMA is typically reported as positive or negative (with a titer dilution such as 1:5 or 1:10).

Because of its near-perfect specificity, a positive EMA essentially confirms that the tTG-IgA result is a true positive. The ESPGHAN no-biopsy pathway for children requires both tTG-IgA ≥10x ULN and a positive EMA on a separately drawn sample [4]. For adults, the ACG still recommends biopsy confirmation for most patients, though growing evidence supports the no-biopsy approach in selected adult cases as well.

Dr. Benjamin Lebwohl, Director of Clinical Research at the Celiac Disease Center at Columbia University, has noted: "EMA is not ideal as a first-line screening test because it requires skilled laboratory interpretation and is more expensive, but when positive it gives clinicians very high confidence in the diagnosis" [8].

A negative EMA with a positive tTG-IgA (especially if tTG-IgA is only mildly elevated at <2x ULN) raises the possibility of a false-positive tTG-IgA. In this situation, repeat testing or proceeding to biopsy is the standard approach.

DGP Antibodies: When and Why They Matter

Deamidated gliadin peptide (DGP) antibodies come in two flavors: DGP-IgA and DGP-IgG. These newer-generation tests replaced the older anti-gliadin antibody (AGA) tests, which had unacceptably high false-positive rates. DGP assays detect antibodies against specific deamidated peptide fragments of gliadin and offer significantly improved performance.

DGP-IgG is the clinically critical one. It serves as the primary alternative screening test when total IgA is deficient [1]. A meta-analysis published in Alimentary Pharmacology & Therapeutics reported DGP-IgG sensitivity of approximately 88% and specificity of 95% for untreated celiac disease [9]. Those numbers are slightly lower than tTG-IgA, which is why DGP-IgG is a backup rather than a frontline test.

DGP-IgA adds marginal value when tTG-IgA is already included. Some labs bundle it into the panel by default. One scenario where DGP markers add clinical value is in children under age 2, where tTG-IgA can be less reliable and DGP antibodies may appear earlier in the disease course [10].

Reading Your Results: A Step-by-Step Framework

Interpreting a celiac panel follows a decision tree. Start with total IgA, then move to the antibody markers.

Step 1: Check total IgA. If total IgA is within normal range (typically 70-400 mg/dL in adults), proceed to interpret IgA-based markers. If total IgA is low (<7 mg/dL), disregard IgA-based markers and rely on DGP-IgG and tTG-IgG instead.

Step 2: Read tTG-IgA. A negative result (<4 U/mL on most assays) with normal total IgA makes celiac disease unlikely, with a negative predictive value exceeding 99% in low-risk populations [3]. A positive result warrants further evaluation.

Step 3: Assess the magnitude. A tTG-IgA ≥10x ULN with a positive EMA is highly predictive of villous atrophy (PPV >95%) [5]. A mildly elevated tTG-IgA (1-3x ULN) requires biopsy to differentiate true celiac from a false positive.

Step 4: Factor in clinical context. A patient with iron-deficiency anemia, chronic bloating, and tTG-IgA of 85 U/mL (12x ULN) has a near-certain celiac diagnosis. A patient with type 1 diabetes, no GI symptoms, and tTG-IgA of 12 U/mL (1.7x ULN) needs biopsy and possibly repeat serology in 3-6 months. Context determines the next step, not the number alone.

The ACG guideline states: "All adult patients with positive celiac serologies should undergo upper endoscopy with multiple biopsies of the duodenum" [1]. While no-biopsy pathways are gaining acceptance, especially after ESPGHAN and the 2023 British Society of Gastroenterology (BSG) update, the standard of care for adults in the United States still includes histological confirmation in most cases [11].

Why Your Panel Might Be Wrong

Celiac serology is good. It is not perfect. False negatives occur in 4-7% of biopsy-confirmed celiac cases, and understanding why prevents missed diagnoses.

Gluten-free or low-gluten diet before testing. This is the most common cause of false negatives. Antibody levels drop within weeks to months of gluten elimination. The ACG recommends consuming the equivalent of at least 1-2 slices of wheat bread daily for 6-8 weeks before testing to ensure reliable results [1]. A 2013 study found that even 3 grams of gluten daily (roughly one slice of bread) for 2 weeks was insufficient for reliable serology in some patients [12].

IgA deficiency (covered above). Accounts for 2-3% of false negatives.

Early or mild disease. Patients with Marsh 1-2 histology (increased intraepithelial lymphocytes without villous atrophy) may have negative serology. A study by Abrams et al. demonstrated that tTG-IgA sensitivity drops to approximately 70% in patients with Marsh 1-2 lesions compared to >95% in Marsh 3 [13].

Immunosuppressive medications. Drugs that suppress antibody production (rituximab, mycophenolate, high-dose corticosteroids) can blunt the serological response.

False positives are less common but clinically relevant. Transient tTG-IgA elevations have been documented during acute viral infections, after surgery, and in liver cirrhosis [6]. Autoimmune thyroid disease, which shares HLA-DQ2/DQ8 haplotypes with celiac disease, produces mildly positive tTG-IgA in 3-5% of cases without true celiac pathology. Biopsy resolves the ambiguity.

What "Normal" Actually Means

Reference ranges for tTG-IgA vary between laboratories because different manufacturers use different assays and calibration standards. A result of <4 U/mL is negative on the INOVA QUANTA Lite assay, while the Euroimmun assay uses <20 RU/mL as its cutoff. Comparing numbers across labs or across time points using different assays is unreliable.

What remains consistent across assays is that a strongly positive result (≥10x ULN) predicts villous atrophy regardless of which kit was used. The ESPGHAN guideline specifically validated the 10x threshold across multiple commercial tTG-IgA assays from different manufacturers [4].

For DGP-IgG, normal is typically <20 U or negative, depending on the assay. For total IgA, the adult reference range is approximately 70-400 mg/dL, though some labs use 61-356 mg/dL. Ask which assay your lab used if you are comparing results over time.

A "normal celiac panel" means all antibody markers are within reference range while total IgA is sufficient. This combination provides a negative predictive value greater than 99% for celiac disease in the general population [3]. In high-risk groups (first-degree relatives of celiac patients, patients with type 1 diabetes or autoimmune thyroiditis), a negative panel may warrant repeat testing in 1-2 years given the 5-10% lifetime risk of developing celiac disease in these populations [14].

Monitoring Treatment: How the Panel Tracks Recovery

After diagnosis and initiation of a strict gluten-free diet, tTG-IgA is the primary marker used to monitor adherence and mucosal recovery. Levels typically decline by 50% within the first 3 months and normalize within 6-12 months on a strict gluten-free diet [15].

Dr. Peter Green, Director of the Celiac Disease Center at Columbia University, has stated: "Persistent elevation of tTG-IgA beyond 12 months on a gluten-free diet should prompt investigation for ongoing gluten exposure, which is by far the most common cause, or consideration of refractory celiac disease in rare cases" [16].

A 2020 study in The American Journal of Gastroenterology found that tTG-IgA normalization within 12 months occurred in 83% of newly diagnosed adults on a gluten-free diet, while 17% had persistently elevated antibodies primarily due to inadvertent gluten exposure [15]. Repeat biopsy is recommended 1-2 years after diagnosis per ACG guidelines to confirm mucosal healing, though some clinicians use normalization of tTG-IgA as a surrogate marker.

Intentionally "raising" or "lowering" your celiac panel results has no clinical purpose outside of the diagnostic gluten challenge context. The antibodies reflect immune activity against gluten. The only way to lower them is to eliminate gluten from the diet completely. There is no medication, supplement, or intervention that reduces celiac antibody levels while continuing to consume gluten.

Celiac Panel in the Context of Related Conditions

Celiac disease shares clinical and genetic features with several conditions commonly evaluated in hormone and metabolic health. Understanding this overlap matters for interpretation.

Hypothyroidism. Celiac disease and autoimmune thyroiditis (Hashimoto's) share HLA-DQ2/DQ8 genetics. The prevalence of celiac disease among autoimmune thyroid patients is approximately 2-5%, compared to 1% in the general population [17]. The Endocrine Society and AACE guidelines recommend screening for celiac disease in patients with unexplained hypothyroid symptoms that persist despite adequate levothyroxine, because gluten-induced intestinal damage can impair thyroid medication absorption.

Iron and B12 deficiency. Celiac disease is found in 3-5% of patients with unexplained iron-deficiency anemia and is a recognized cause of vitamin B12 malabsorption, particularly when damage extends beyond the proximal duodenum [18]. The USPSTF and AGA recommend celiac screening in adults with iron-deficiency anemia unresponsive to oral supplementation.

Type 1 diabetes. The prevalence of celiac disease among type 1 diabetics is approximately 5-8%, making regular screening with tTG-IgA a standard recommendation from the ADA [1].

Identify the clinical trail that led to the celiac panel order. The result gains meaning when interpreted alongside the reason it was ordered.